Smith Karen L. — SEC Form 4 filings
SEC reporting owner CIK 1639637. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-06-06 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 5,241 shares, $44,182 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 5,241 shares @ $8.43 ($44,182) in Aurinia Pharmaceuticals Inc., filed 2024-11-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | Director | 2 | — | 1 leg · 5,241 sh · $44,182 | 4 |
| Skye Bioscience, Inc. (SKYE) | Director | 5 | — | — | 5 |
| SANGAMO THERAPEUTICS, INC (SGMO) | Director | 2 | — | — | 4 |
| Context Therapeutics Inc. (CNTX) | Director | 3 | — | — | 3 |
Form 4 filings — Smith Karen L.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Context Therapeutics Inc. (CNTX) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | SANGAMO THERAPEUTICS, INC (SGMO) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Context Therapeutics Inc. (CNTX) | Grant/award (A): 123,500 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Grant/award (A): 12,135 @ $0 · Grant/award (A): 18,641 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Aurinia Pharmaceuticals Inc. (AUPH) | Option exercise (M): 17,913 · Sale (S): 5,241 @ $8.43 · Option exercise (M): 17,913 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Context Therapeutics Inc. (CNTX) | Grant/award (A): 19,315 (derivative) @ $0 | EDGAR |
| 2024-07-05 | 4 | Skye Bioscience, Inc. (SKYE) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | SANGAMO THERAPEUTICS, INC (SGMO) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1639637 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →